Selection and determination of specific cells, useful particularly for diagnosis and monitoring of tumors, by antibody-mediated selection then detecting specific mRNA

Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample, is new. Method for selection and/or qualitative and/or quantitative determination of predetermined cells (A) from (or in) a sample comprises treating the sample with: (i) a predetermined combination of at least two antibodies (Ab) and/or Ab derivatives which bind preferentially to different epitopes on (A); and/or (ii) at least one bispecific antibody (2Ab) and/or derivative which binds preferentially to different epitopes on (A). Cells labeled with at least one antibody are separated and tested with a predetermined combination of at least two molecular-biology detection reagents (R) that react with at least one component of (A). An Independent claim is also included for a diagnostic kit for the method comprising: (i) Ab and/or 2Ab; and (ii) (R). Die vorliegende Erfindung betrifft ein Verfahren zur Diagnostik oder Behandlungskontrolle von Brustkrebs bei einem Menschen, wobei in einer Blutprobe des Menschen das Vorhandensein oder Fehlen von mRNS erfaßt wird, die für mindestens eines der Tumormarkerproteine EGF-R, CEA, Stanniocalcin, CK20, MAGE-3 und/oder CA-15 (III) kodiert und daraus auf das Vorhandensein von Mammakarzinomzellen in der Blutprobe und damit auf mögliche Metastasierung geschlossen wird.